Study Finds Evidence Of Higher Consciousness From Psychedelics
Scientists have found the first evidence of a higher state of consciousness by measuring the complexity of brain activity of people under the influence of psychedelics. The study measured magnetic fields generated by brain activity and used the data to create an index of varying levels of consciousness.
The study, conducted by a team at the University of Sussex in England, looked at the diversity of brain signals, a measure of the complexity of brain activity, in people under the influence of psilocybin, LSD, and ketamine, compared to the brain activity of people in lower levels of consciousness, such as sleep, anesthesia, and ‘vegetative’ states.
Participants under the influence of these drugs showed higher than baseline diversity, or higher levels than someone who is simply awake. This is the first time a measure of an elevated consciousness has been recorded in a study of its kind.
The researchers were quick to point out that their measure of higher consciousness doesn’t necessarily imply that the psychedelic state is better or higher functioning than our normal waking state. Instead the index they’ve used shows that the psychedelic state increases small magnetic fields produced by the brain and higher neural-signal diversity in all three types of drugs.
According to the study, “During the psychedelic state, the electrical activity of the brain is less predictable and less ‘integrated’ than during normal conscious wakefulness.”
One researcher involved in the study, Dr. Muthukumaraswamy, said he was surprised the results were consistent with each drug, despite their differing pharmacology. He and his colleagues believe that their research could lead to carefully-controlled use of the drug for therapeutic treatment in patients suffering from severe depression.
The group found correlation between participants’ reports of changes in intensity of the psychedelic experience and changes in brain signal diversity. They believe this shows there is a difference in aspects of brain activity in our everyday conscious experience.
This study comes after recent trials have shown psilocybin can flip a “reset” mechanism in the brains of people suffering from depression. Similar studies found benefits in the therapeutic use of ketamine and LSD for people suffering from a range of physical and psychiatric issues, including drug addiction and PTSD.
Similar studies have been conducted to test electroencephalography, or EEG, on participants in deep states of meditation, finding increased levels of alpha and theta wave activity. It’s unclear whether this recent study plans on testing participants levels of brain-signal diversity in non-intoxicated, altered states of consciousness.
About the Author
Study Shows Microdosing Psilocybin Boosts Mood, Mental Health
A new study provides the most compelling evidence to date on the impressive mental health benefits of microdosing psilocybin.
While there has been an ever-increasing number of studies showing the efficacy of treatment of mental health disorders with psychedelics, there has been relatively little research on the practice of microdosing.
Microdosing, or repeatedly taking small, barely perceptible amounts of psychedelics, has been exponentially increasing in popularity, with a wide range of people reporting a multitude of improvements to their psychological wellbeing.
The latest scientific study to look at the effects of microdosing was conducted by researchers at the University of British Columbia, as well as other leaders in the fields of psychology and mycology. The study followed 953 people who used small, repeated doses of psilocybin for about 30 days, as well as a control group who did not microdose.
While the exact dosages of psylocibin that participants self-administered varied somewhat, they were all low enough to not impact daily functioning.
Over a one-month period, participants took these psylocibin microdoses three to five times per week and were asked to complete a number of assessments through a smartphone app that tracked their mental health symptoms, mood, and measures of cognition. The findings definitively showed that the microdosing participants demonstrated greater improvements in mood and mental health than those in the non-microdosing control group.
